Janux Therapeutics Inc (JANX)
47.11
-0.40
(-0.84%)
USD |
NASDAQ |
May 17, 16:00
47.11
0.00 (0.00%)
After-Hours: 20:00
Janux Therapeutics Cash from Investing (Quarterly): -113.74M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -113.74M |
| December 31, 2023 | 11.12M |
| September 30, 2023 | -61.45M |
| June 30, 2023 | 17.87M |
| March 31, 2023 | -8.74M |
| December 31, 2022 | -1.604M |
| September 30, 2022 | 19.76M |
| June 30, 2022 | 9.039M |
| March 31, 2022 | 31.07M |
| Date | Value |
|---|---|
| December 31, 2021 | 7.326M |
| September 30, 2021 | -205.54M |
| June 30, 2021 | -142.60M |
| March 31, 2021 | -0.153M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-205.54M
Minimum
Sep 2021
31.07M
Maximum
Mar 2022
-25.74M
Average
--
Median
Mar 2020
Cash from Investing (Quarterly) Benchmarks
| Viking Therapeutics Inc | -459.79M |
| Equillium Inc | -2.831M |
| Minerva Neurosciences Inc | 0.00 |
| Arvinas Inc | -127.80M |
| Calidi Biotherapeutics Inc | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.84M |
| Cash from Financing (Quarterly) | 322.17M |
| Free Cash Flow | -53.26M |
| Free Cash Flow Per Share (Quarterly) | -0.3065 |
| Free Cash Flow to Equity (Quarterly) | -15.03M |
| Free Cash Flow Yield | -2.47% |